Developer docs
API playgroundTry for free, no card

Search company profiles

ARIZ Precision Medicine

Full company profile

uuid000355y

Namestring
ARIZ Precision Medicine
Legal namestring
ARIZ Precision Medicine, Inc.
Websiteurl
arizbio.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

ARIZ Precision Medicine is a privately held, pre-clinical stage biopharmaceutical company founded in 2016 (per corporate history) and headquartered in Davis, California. The company develops precision ligand-targeted siRNA cancer therapies designed to destroy cancer driver proteins while sparing healthy cells. Its therapeutic strategy targets PRDM (Positive Regulatory Domain-containing Methyltransferases) genes and proteins, which the company characterizes as master regulators of gene expression that control cell differentiation and proliferation. ARIZ serves the oncology market across multiple indications, including lung, breast, colon, multiple myeloma, leukemia, prostate, liver, and lymphoma.

ARIZ's core technology is the PRDM Oncogene Targeting Platform, which combines siRNA compounds with targeting peptides and PEG-protected nanoparticle drug delivery systems to concentrate drug payloads inside cancer cells while leaving normal cells largely undamaged. Pre-clinical data shows the lead candidate, ARIZ-047, can eliminate over 90% of lung cancer cells (A549) in cell culture with a single low dose while affecting only 5-10% of normal cells, with efficacy also demonstrated in animal models. The platform is protected by a broad IP portfolio including issued US Patent 12,012,597 B2 covering pharmaceutical compositions and methods for treating cancer using siRNA to modulate PRDM2/RIZ protein, plus licensed PRDM gene/protein patents and additional provisional composition-of-matter patents.

ARIZ operates an asset-light, partnership-driven business model with no current product revenue. Monetization is planned through licensing deals, milestone payments, and royalty streams generated via strategic partnerships with large pharmaceutical companies for clinical development and commercialization. As of late 2024, ARIZ has raised approximately $2.61 million in cumulative funding across seed and angel rounds, with named investors including Moneta Ventures and Sacramento Angels, plus 13 angel investors at AngelCon. The company builds visibility and partnership pipeline through industry channels including BIO International Convention, the J.P. Morgan Healthcare Conference (J&J Innovation Quick Pitch, 2020), and the CLSI FAST Advisory Program, and has earned recognition including the BUZZ of BIO award (2020) and Golden Tickets to Bakar Labs (2024).

Short descriptiontext

ARIZ Precision Medicine is a pre-clinical biopharmaceutical company developing precision siRNA cancer therapies that target PRDM oncogenes via nanoparticle drug delivery, with lead candidate ARIZ-047 aimed at lung cancer and a pipeline spanning multiple oncology indications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersDavis, United States
HQ citystring
Davis
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision cancer medicine, siRNA oncology therapeutics, nanoparticle drug delivery, nucleic acid therapy, preclinical biopharmaceutical development
Industry5 codes
PRIMARYHLAAADAB
siRNA Therapeutics (gene silencing)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Precision Oncology Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Drug Development and Licensing
TypeLicensing Royalties
Description

Pre-clinical biopharmaceutical company developing precision ligand targeted siRNA cancer therapies. Revenue model is expected to come from pharmaceutical partnerships, licensing deals, and eventual product commercialization upon FDA approval. Currently in pre-clinical stage with no revenue.

arizbio.com
2Strategic Partnerships
TypeLicensing Royalties
Description

The company seeks to partner with pharmaceutical companies to advance products through clinical development and commercialization, generating partnership fees, milestone payments, and royalty streams.

arizbio.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

ARIZ Precision Medicine is a preclinical-stage biopharmaceutical company developing precision ligand-targeted siRNA (small interfering RNA) cancer therapies. Its lead drug candidate, ARIZ-047, uses siRNA combined with nanoparticle drug delivery systems to target and modulate PRDM (Positive Regulatory Domain-containing Methyltransferases) oncogenes, with demonstrated efficacy in killing lung cancer cells in cell culture and animal models. The company is pursuing strategic partnerships with pharmaceutical companies for clinical development and eventual commercialization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Kills >90% of cancer cells in cell culture with single low dose while only affecting 5-10% of normal cells
+1 more record
Product overview1 text field

ARIZ Precision Medicine is a preclinical stage biopharmaceutical company developing precision ligand targeted siRNA cancer therapies. The company's core offering is the PRDM Oncogene Targeting Platform™, which uses siRNA technology combined with nanotechnology-based drug delivery systems to modulate PRDM genes and proteins. Lead drug candidate ARIZ-047 targets lung cancer cells. The platform addresses multiple cancer types including lung, breast, colon, myeloma, leukemia, prostate, liver, and lymphoma through different PRDM targets (PRDM 2, 14, 1, 16).

Product and service2 records
1ARIZ-047
CategoryDrug candidate
Description

A highly specific siRNA drug candidate using precision ligand targeted siRNA therapy for cancer treatment, demonstrated effective in killing lung cancer cells in both cell culture and animal model experiments. Targets PRDM2/RIZ protein expression and covers a broad range of cancers under US Patent 12,012,597 B2.

2PRDM-targeted siRNA Cancer Therapies
CategoryOncology drug pipeline
Description

A pipeline of small interfering RNA (siRNA) compounds designed to target and destroy cancer cell driver proteins via PRDM gene modulation, combined with targeting peptides and nanoparticle drug delivery systems. Addresses multiple cancer types including lung, breast, colon, myeloma, leukemia, prostate, liver, and lymphoma through different PRDM targets (PRDM 2, 14, 1, 16).

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1NATA (Nucleic Acid Therapy Accelerator)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-21
Description

Collaboration between ARIZ and MRC's Nucleic Acid Therapy Accelerator to harness their combined platforms to develop nucleic acid therapy drug candidates for novel gene targets with strong genetic associations to leading cancers. Combines NATA's expertise in NAT design with ARIZ's RNAi compounds for treating a range of cancers.

arizbio.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-07-11
Description

ARIZ won Golden Tickets to Bakar Labs sponsored by BrightEdge/American Cancer Society. This provides access to laboratory space and resources for biotech development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-14
Description

ARIZ is affiliated with University of California, Davis as a participant in the UCD Venture Catalyst DRIVE program. Located at UC Davis-HM Clause Life Science Innovation Center for access to research infrastructure and talent.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Alnylam is the leading siRNA therapeutics company with a broad clinical pipeline across multiple therapeutic areas including oncology. It is comparable to ARIZ as the reference siRNA platform against which ARIZ's narrower, cancer-focused siRNA approach is benchmarked.

TypeDirect peer
Description

Arrowhead develops RNAi-based therapeutics with a significant oncology pipeline using proprietary siRNA delivery platforms (TRiM and others). It is the closest direct peer to ARIZ in applying siRNA to oncology targets and competing for pharma partnership attention.

TypeDirect peer
Description

Sirnaomics develops siRNA-based therapeutics with both oncology and anti-fibrotic programs using its PNP (polypeptide nanoparticle) delivery system. It is a direct peer in modality (siRNA + nanoparticle) and target space (cancer).

TypeBroad incumbent
Description

Dicerna was a clinical-stage siRNA company acquired by Novo Nordisk. It is comparable as a precedent for how a siRNA platform developer can be acquired, providing a relevant valuation and strategic-exit benchmark for ARIZ.

TypeEmerging player
Description

Phio is developing RNAi-based therapeutics for cancer and other indications using its self-delivering RNAi platform. Comparable to ARIZ as a smaller, cancer-focused siRNA peer competing for similar partnership and investment capital.

TypeEmerging player
Description

Arcturus develops RNA-based therapeutics including siRNA and mRNA candidates, with oncology and rare disease programs. It is comparable as another RNA-medicine platform with adjacent delivery technology and oncology ambitions.

TypeEmerging player
Description

MiNA develops RNA-based therapeutics, primarily saRNA (small activating RNA), for cancer and other diseases. Comparable as a precision RNA oncology platform with a similar size, stage, and partnership-driven business model.

TypeEmerging player
Description

Praxis is a clinical-stage precision medicine company targeting CNS disorders with genetically defined patient populations. Comparable as a similarly sized precision-medicine platform that licenses or partners early-stage assets in tightly defined indications.

9Silenseed
TypeEmerging player
Description

Silenseed is developing siRNA-based therapeutics delivered via its siGLOBE platform, with oncology applications. Comparable as a small, cancer-focused siRNA platform targeting solid tumors.

TypeOthers
Description

Genevant is a lipid nanoparticle (LNP) delivery technology company spun out of Arbutus, enabling RNA therapeutics including siRNA. Comparable as an enabling technology player whose delivery IP overlaps with ARIZ's nanoparticle delivery approach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ARIZ Precision Medicine

Precision Oncology Therapeuticsarizbio.com

ARIZ Precision Medicine is a pre-clinical biopharmaceutical company developing precision siRNA cancer therapies that target PRDM oncogenes via nanoparticle drug delivery, with lead candidate ARIZ-047 aimed at lung cancer and a pipeline spanning multiple oncology indications.

What ARIZ Precision Medicine does

ARIZ Precision Medicine is a privately held, pre-clinical stage biopharmaceutical company founded in 2016 (per corporate history) and headquartered in Davis, California. The company develops precision ligand-targeted siRNA cancer therapies designed to destroy cancer driver proteins while sparing healthy cells. Its therapeutic strategy targets PRDM (Positive Regulatory Domain-containing Methyltransferases) genes and proteins, which the company characterizes as master regulators of gene expression that control cell differentiation and proliferation. ARIZ serves the oncology market across multiple indications, including lung, breast, colon, multiple myeloma, leukemia, prostate, liver, and lymphoma.

ARIZ's core technology is the PRDM Oncogene Targeting Platform, which combines siRNA compounds with targeting peptides and PEG-protected nanoparticle drug delivery systems to concentrate drug payloads inside cancer cells while leaving normal cells largely undamaged. Pre-clinical data shows the lead candidate, ARIZ-047, can eliminate over 90% of lung cancer cells (A549) in cell culture with a single low dose while affecting only 5-10% of normal cells, with efficacy also demonstrated in animal models. The platform is protected by a broad IP portfolio including issued US Patent 12,012,597 B2 covering pharmaceutical compositions and methods for treating cancer using siRNA to modulate PRDM2/RIZ protein, plus licensed PRDM gene/protein patents and additional provisional composition-of-matter patents.

ARIZ operates an asset-light, partnership-driven business model with no current product revenue. Monetization is planned through licensing deals, milestone payments, and royalty streams generated via strategic partnerships with large pharmaceutical companies for clinical development and commercialization. As of late 2024, ARIZ has raised approximately $2.61 million in cumulative funding across seed and angel rounds, with named investors including Moneta Ventures and Sacramento Angels, plus 13 angel investors at AngelCon. The company builds visibility and partnership pipeline through industry channels including BIO International Convention, the J.P. Morgan Healthcare Conference (J&J Innovation Quick Pitch, 2020), and the CLSI FAST Advisory Program, and has earned recognition including the BUZZ of BIO award (2020) and Golden Tickets to Bakar Labs (2024).

ARIZ Precision Medicine firmographics

Firmographics
Name
ARIZ Precision Medicine
Legal name
ARIZ Precision Medicine, Inc.
Website
https://arizbio.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
1–10 employees
Short description
ARIZ Precision Medicine is a pre-clinical biopharmaceutical company developing precision siRNA cancer therapies that target PRDM oncogenes via nanoparticle drug delivery, with lead candidate ARIZ-047 aimed at lung cancer and a pipeline spanning multiple oncology indications.
Ownership category
akta.pro rank

ARIZ Precision Medicine industry classification

Industry
Product category
Precision Oncology Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAADAB
siRNA Therapeutics (gene silencing)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Precision cancer medicine
  • SiRNA oncology therapeutics
  • Nanoparticle drug delivery
  • Nucleic acid therapy
  • Preclinical biopharmaceutical development

Where ARIZ Precision Medicine is headquartered

Location

Headquarters

HQ city
Davis
HQ country
United States
HQ region
North America

Offices1 record

Markets served

ARIZ Precision Medicine business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Drug Development and Licensing: Pre-clinical biopharmaceutical company developing precision ligand targeted siRNA cancer therapies. Revenue model is expected to come from pharmaceutical partnerships, licensing deals, and eventual product commercialization upon FDA approval. Currently in pre-clinical stage with no revenue.
  2. Strategic Partnerships: The company seeks to partner with pharmaceutical companies to advance products through clinical development and commercialization, generating partnership fees, milestone payments, and royalty streams.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

ARIZ Precision Medicine product offering

Product offering

Core offering

ARIZ Precision Medicine is a preclinical-stage biopharmaceutical company developing precision ligand-targeted siRNA (small interfering RNA) cancer therapies. Its lead drug candidate, ARIZ-047, uses siRNA combined with nanoparticle drug delivery systems to target and modulate PRDM (Positive Regulatory Domain-containing Methyltransferases) oncogenes, with demonstrated efficacy in killing lung cancer cells in cell culture and animal models. The company is pursuing strategic partnerships with pharmaceutical companies for clinical development and eventual commercialization.

Product overview

ARIZ Precision Medicine is a preclinical stage biopharmaceutical company developing precision ligand targeted siRNA cancer therapies. The company's core offering is the PRDM Oncogene Targeting Platform™, which uses siRNA technology combined with nanotechnology-based drug delivery systems to modulate PRDM genes and proteins. Lead drug candidate ARIZ-047 targets lung cancer cells. The platform addresses multiple cancer types including lung, breast, colon, myeloma, leukemia, prostate, liver, and lymphoma through different PRDM targets (PRDM 2, 14, 1, 16).

Differentiator

Problem solved

Functional benefit

Products and services

  • ARIZ-047 A highly specific siRNA drug candidate using precision ligand targeted siRNA therapy for cancer treatment, demonstrated effective in killing lung cancer cells in both cell culture and animal model experiments. Targets PRDM2/RIZ protein expression and covers a broad range of cancers under US Patent 12,012,597 B2.
  • PRDM-targeted siRNA Cancer Therapies A pipeline of small interfering RNA (siRNA) compounds designed to target and destroy cancer cell driver proteins via PRDM gene modulation, combined with targeting peptides and nanoparticle drug delivery systems. Addresses multiple cancer types including lung, breast, colon, myeloma, leukemia, prostate, liver, and lymphoma through different PRDM targets (PRDM 2, 14, 1, 16).

Quantifiable outcome

  • Kills >90% of cancer cells in cell culture with single low dose while only affecting 5-10% of normal cells
  • +1 more outcomes

Companies that use ARIZ Precision Medicine

Customer profile

Segments2 records

Ideal customer profiles2 records

ARIZ Precision Medicine technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

ARIZ Precision Medicine partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • NATA (Nucleic Acid Therapy Accelerator)coreStrategic or Co-development Partner · 21 November 2024Collaboration between ARIZ and MRC's Nucleic Acid Therapy Accelerator to harness their combined platforms to develop nucleic acid therapy drug candidates for novel gene targets with strong genetic associations to leading cancers. Combines NATA's expertise in NAT design with ARIZ's RNAi compounds for treating a range of cancers.
  • Bakar LabscoreStrategic or Co-development Partner · 11 July 2024ARIZ won Golden Tickets to Bakar Labs sponsored by BrightEdge/American Cancer Society. This provides access to laboratory space and resources for biotech development.
  • UC Davis (UCD Venture Catalyst DRIVE program)coreStrategic or Co-development Partner · 14 January 2020ARIZ is affiliated with University of California, Davis as a participant in the UCD Venture Catalyst DRIVE program. Located at UC Davis-HM Clause Life Science Innovation Center for access to research infrastructure and talent.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

ARIZ Precision Medicine competitors and assessment

Company assessment

Broad incumbents

  • Alnylam Pharmaceuticals: Alnylam is the leading siRNA therapeutics company with a broad clinical pipeline across multiple therapeutic areas including oncology. It is comparable to ARIZ as the reference siRNA platform against which ARIZ's narrower, cancer-focused siRNA approach is benchmarked.
  • Dicerna Pharmaceuticals (Novo Nordisk): Dicerna was a clinical-stage siRNA company acquired by Novo Nordisk. It is comparable as a precedent for how a siRNA platform developer can be acquired, providing a relevant valuation and strategic-exit benchmark for ARIZ.

Direct peers

  • Arrowhead Pharmaceuticals: Arrowhead develops RNAi-based therapeutics with a significant oncology pipeline using proprietary siRNA delivery platforms (TRiM and others). It is the closest direct peer to ARIZ in applying siRNA to oncology targets and competing for pharma partnership attention.
  • Sirnaomics: Sirnaomics develops siRNA-based therapeutics with both oncology and anti-fibrotic programs using its PNP (polypeptide nanoparticle) delivery system. It is a direct peer in modality (siRNA + nanoparticle) and target space (cancer).

Emerging players

  • Phio Pharmaceuticals: Phio is developing RNAi-based therapeutics for cancer and other indications using its self-delivering RNAi platform. Comparable to ARIZ as a smaller, cancer-focused siRNA peer competing for similar partnership and investment capital.
  • Arcturus Therapeutics: Arcturus develops RNA-based therapeutics including siRNA and mRNA candidates, with oncology and rare disease programs. It is comparable as another RNA-medicine platform with adjacent delivery technology and oncology ambitions.
  • MiNA Therapeutics: MiNA develops RNA-based therapeutics, primarily saRNA (small activating RNA), for cancer and other diseases. Comparable as a precision RNA oncology platform with a similar size, stage, and partnership-driven business model.
  • Praxis Precision Medicines: Praxis is a clinical-stage precision medicine company targeting CNS disorders with genetically defined patient populations. Comparable as a similarly sized precision-medicine platform that licenses or partners early-stage assets in tightly defined indications.
  • Silenseed: Silenseed is developing siRNA-based therapeutics delivered via its siGLOBE platform, with oncology applications. Comparable as a small, cancer-focused siRNA platform targeting solid tumors.

Others

  • Genevant Sciences: Genevant is a lipid nanoparticle (LNP) delivery technology company spun out of Arbutus, enabling RNA therapeutics including siRNA. Comparable as an enabling technology player whose delivery IP overlaps with ARIZ's nanoparticle delivery approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

ARIZ Precision Medicine social profiles

Digital presence

ARIZ Precision Medicine financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ARIZ Precision Medicine leadership team

Management profile

Number of profiles

Profiles12 records

ARIZ Precision Medicine funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ARIZ Precision Medicine M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ARIZ Precision Medicine

What does ARIZ Precision Medicine do?

ARIZ Precision Medicine is a preclinical-stage biopharmaceutical company developing precision ligand-targeted siRNA (small interfering RNA) cancer therapies. Its lead drug candidate, ARIZ-047, uses siRNA combined with nanoparticle drug delivery systems to target and modulate PRDM (Positive Regulatory Domain-containing Methyltransferases) oncogenes, with demonstrated efficacy in killing lung cancer cells in cell culture and animal models. The company is pursuing strategic partnerships with pharmaceutical companies for clinical development and eventual commercialization.

Is ARIZ Precision Medicine a public or private company?

ARIZ Precision Medicine is a private company. It is classified as venture growth investor backed and is currently operating.

When was ARIZ Precision Medicine founded?

ARIZ Precision Medicine was founded in 2016. It employs 1 to 10 people.

Where is ARIZ Precision Medicine based?

ARIZ Precision Medicine is headquartered in Davis, United States, in the North America region.

How does ARIZ Precision Medicine make money?

Two revenue lines are on record. Drug Development and Licensing is the primary driver. The others are strategic Partnerships.

Who are ARIZ Precision Medicine's main competitors?

Broad incumbents on record are Alnylam Pharmaceuticals and Dicerna Pharmaceuticals (Novo Nordisk). Direct peers are Arrowhead Pharmaceuticals and Sirnaomics. Emerging players are Phio Pharmaceuticals, Arcturus Therapeutics, MiNA Therapeutics, Praxis Precision Medicines and Silenseed. Genevant Sciences is listed as an others.

Does ARIZ Precision Medicine have an API?

No public API is recorded for ARIZ Precision Medicine.

What industry is ARIZ Precision Medicine in?

ARIZ Precision Medicine's product category is Precision Oncology Therapeutics. Its primary akta.pro industry code is HLAAADAB, siRNA Therapeutics (gene silencing), with a secondary code of HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales